GLOBAL BENIGN PROSTATIC HYPERPLASIA (BPH) DEVICES MARKET SIZE TO CROSS USD 800 MILLION BY 2020, GROWING AT A CAGR OF OVER 22% DURING THE FORECAST PERIOD

Benign Prostatic Hyperplasia (BPH) Devices Market Size, Share, Trends, Analysis Report by Procedure (Prostatic Urethral Lift (PUL), Laser Therapy, Transurethral Resection of the Prostate (TURP) and Others), End-users (Hospitals, Specialty Urology Centers, and Ambulatory Surgery Centers (ASC)) and Geography (APAC, Europe, North America, Latin America, and Middle East & Africa) Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Landscape, Market Share & Forecast, 2020–2025

GET ACTIONABLE INSIGHTS ON HOW COVID-19 IS IMPACTING YOUR BUSINESS
Enquire Now Customize this Report

Most Exhaustive Report

230 Pages

59 Tables

106 Charts

5 Regions

16 Countries

19 Companies

3 Market Segment

BENIGN PROSTATIC HYPERPLASIA DEVICES MARKET REPORT SCOPE

Report Attribute Details
Market Size (Revenue) USD 800 Million (2020)
CAGR 22% (2020-2025)
Base Year 2019
Forecast Year 2020-2025
Market Segments Procedure (Prostatic Urethral Lift (PUL), Laser Therapy, Transurethral Resection of the Prostate (TURP) and Others), End-users (Hospitals, Specialty Urology Centers, and Ambulatory Surgery Centers (ASC))
Geographic Analysis APAC, Europe, North America, Latin America, and Middle East & Africa
Countries Covered Spain, Germany, Italy, France, UK, US, Canada, South Korea, China, Japan, Australia, India, Brazil, Mexico, Turkey, and South Africa

INDUSTRY INSIGHTS

The global benign prostatic hyperplasia (BPH) devices market size to cross USD 800 million by 2020, growing at a CAGR of over 22% during the forecast period. The global benign prostatic hyperplasia (BPH) devices market is expected to observe an absolute growth of over 242% during the forecast period. The market is growing due to several factors; however, the growing number of the elderly men population is a primary factor responsible for influencing the growth of the BPH devices market. BPH is one of the most common diseases in men, which generally develops after the age of 40 years, with a prevalence rate of around 8–60% between 40 and 90 years. Moreover, it affects about 70% of US men between the age of 60 and 69 years. Approximately 32 million men worldwide experience mild to severe symptoms of BPH. According to several medical studies, there are more than 50% of men above age 50 diagnosed with an enlarged prostate. Besides, there are 4 million men who suffer from BPH. Hence, the high prevalence among men is a major factor contributing to the demand for advanced medical devices.

Another factor that is expected to drive the market is the emergence of advanced and innovative BPH therapies to provide quality care to patients in outpatient centers in less time and at an affordable cost. Although medication is the first line of treatment preferred by several patients, around 45 to 60% of patients tend to opt for advanced therapies to relief from lower urinary tract symptoms (LUTS) and other complications immediately. Hence, the emergence of innovative BPH treatment devices is expected to reduce complications associated with traditional BPH treatment, thereby driving the demand for advanced devices.

SNIPPETS

  • Europe and North America are expected to grow at the faster CAGRs than the average global market due to the strong presence of major vendors and the increasing patient population
  • The global specialty urology clinics segment is expected to grow at a CAGR of over 30% during the 2019–2025
  • The prostatic urethral lift segment is expected to observe an incremental growth of over $1.4 billion by 2025 on account of the increasing adoption and popularity of advanced minimally invasive treatment options.

BENIGN PROSTATIC HYPERPLASIA DEVICES MARKET SEGMENTATION

This research report includes a detailed segmentation by

  • Procedure
  • End-user
  • Geography

INSIGHTS BY PROCEDURE 

The PUL technology segment is growing due to the increasing patient population and the growing adoption of advanced minimally invasive treatment. PUL is an advanced minimally invasive procedure for the treatment of BPH with less complications. As these procedures can be performed under local, spinal, or general anesthesia or in in-office settings or clinics, the technique is grabbing attention among end-users in developed economies, thereby influencing the segment.

The laser segment is growing at a significant rate due to the increasing awareness of BPH, and several treatment options using advanced medical devices. As there is a rise in the number of the patient population, the demand for laser therapies is likely to grow. Also, an accelerated demand for medical lasers is observed to treat multiple diseases, this is increasing the demand for non-invasive treatment devices among end-users, thereby driving the growth in the benign prostatic hyperplasia devices market.

Transurethral resection procedures (TURP) have been a standard medical procedure for the treatment of BPH in the last more than 60 years. It has been the most suitable treatment for lower urinary tract obstructions caused by BPH. The increase in the elderly population is one of the major factors driving the demand for TURP. The adoption of these procedures is high in hospitals, where there is a scarcity of well-developed innovative devices. However, the availability of advanced treatment options is decreasing the adoption of traditional resectoscope treatment options, thereby influencing the growth during the forecast period.

INSIGHTS BY END-USER

In 2019, the hospital end-user was the largest segment in the global benign prostatic hyperplasia devices market. However, the segment is likely to witness the slowest growth during the forecast period due to the change in patients’ preference in terms of treatment. As BPH surgical treatment is witnessing the application of innovative MI devices, BPH surgical care is moving toward out-patient settings. However, the increasing aging population and the growing patient group with BPH have led to high hospitalization rates. Most patients prefer hospitals, especially public ones, as their priority due to the availability of insurance coverage and less out-of-pocket expenses in case of inadequate reimbursement for BPH surgeries. Further, the availability of skilled healthcare professionals with knowledge and expertise in performing both invasive and MI BPH surgeries also attracts more patients to hospitals.

Specialty urology clinics are expected to grow at a phenomenally rate due to the increased acceptance of several in-office based BPH therapies, especially in North America, Europe, and APAC. In-office therapies are non-surgical procedures performed in the urologist’s clinics in less than one hour. With several research studies confirming minimally Invasive options as safe, effective, and durable for treating BPH, the specialist clinic segment is likely to grow during the forecast period.

The introduction of ASCs has lowered the rate of out-patient urologic surgeries performed in expensive hospital settings. The volume of outpatient surgeries has increased dramatically over the past three decades due to advances in medical technology and payment incentives. ASCs have several advantages, most of which are derived from their operational efficiency. For payers, ASCs provide similar care at a low cost per episode. ASCs offer a patient-centered experience in a comfortable environment with lower co-payments.

INSIGHTS BY GEOGRAPHY

North America is growing at a fast CAGR due to the growing preference for technologically advanced BPH devices. Although the high cost of BPH devices can affect the market adversely, the presence of reimbursement coverage for both invasive and minimally invasive treatment options will have a positive impact on the growth. The availability of reimbursement coverage for several BPH devices is likely to boost the market in the region. North America is currently dominating the TURP segment, with around 150,000 people in the US opting for TURPs annually because of high medical reimbursement facilities. Therefore, the market is growing at significant growth, and the region is dominating the market and expected to dominate in the upcoming years.

Germany, the UK, France, Spain, and Italy are the major revenue contributors in Europe. The benign prostatic hyperplasia devices market is growing at a healthier rate in the APAC, Latin America, and the Middle East & Africa due to the presence of sophisticated healthcare infrastructure. The prevalence of BPH is more than 10.3% in recent years, and the trend is likely to grow due to the increasing elderly population, especially men. According to a survey, around 29% of European men aged between 50 and 80 years have moderate to severe LUTS. As Europe has high availability of skilled professionals and the healthcare infrastructure is well developed for the use of BPH advanced technology such as minimally invasive surgery devices and lasers, the adoption is likely to boost in the region.

Japan is the major revenue contributor to the APAC BPH devices market due to the increasing prevalence and high adoption of TURP and laser therapies for the treatment of patients. China is the second major revenue contributor to the APAC region due to the presence of a large pool of patients that use technologically advanced devices. The demand for TURP is relatively higher in the region than other procedures as this method is clinically proven and widely accepted treatment option for BPH. Laser therapy is also gaining traction in countries such as Japan, Australia, South Korea, China, and India.

INSIGHTS BY VENDORS

The global BPH devices market is fairly concentrated and is characterized by the presence of established vendors holding the majority of the share. There is a significant number of global as well as regional players offering advanced BPH devices in the market. Teleflex, KARL STORZ, Lumenis, Urologix, and Boston Scientific are the key players in the benign prostatic hyperplasia devices market. These companies have a wide geographic footprint, diversified product portfolio, and a strong focus on innovation and research activities.

The benign prostatic hyperplasia (BPH) devices market research report includes in-depth coverage of the industry analysis with revenue and forecast insights for the following segments:

Segmentation by Procedure

  • PUL
  • Laser Therapy
  • TURP
  • Others

By End-user  

  • Hospitals
  • Specialty Urology Centers
  • Ambulatory Surgery Centers (ASC)

By Geography

  • Europe
    • Spain
    • Germany
    • Italy
    • France
    • UK
  • North America
    • US
    • Canada
  • APAC
    • South Korea
    • China
    • Japan
    • Australia
    • India
  • Latin America
    • Brazil
    • Mexico
  • MEA
    • Turkey
    • South Africa

Frequently Asked Questions

The benign prostatic hyperplasia (BPH) devices market size to reach revenues of over $800 million by 2020, growing at a CAGR of around 22% by 2025.
Japan is the major revenue contributor to the APAC BPH devices market due to the increasing prevalence and high adoption of TURP and laser therapies for the treatment of patients.
The laser segment is growing at a significant rate due to the increasing awareness of BPH, and several treatment options using advanced medical devices.
The key vendors in the benign prostatic hyperplasia (BPH) devices market are KARL STORZ, Lumenis, Boston Scientific, Urologix, and Teleflex. The established players hold majority of the market share.
In 2019, the hospital end-user was the largest segment in the global benign prostatic hyperplasia devices market.
Read More

Select a license type that suits your business needs

Single User Licence
$3500.00
  • Report accessible by one user only
  • Free 10% or 3 days of customization
  • Free post-sale service assistance
  • Continuous support through email
Best Value Tag
5 User Licence
$4000.00
  • Report accessible by 5 users within the organization
  • Free 15% or 4.5 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Corporate Licence
$5000.00
  • Free Datasheet worth $1500
  • Report accessible by the entire organization
  • Free 20% or 6 days of customization
  • Free post-sale service assistance
  • Continuous support through email and telephone
  • Direct access to lead analysts
  • Free analyst hour
  • Free Upgrade: If an updated report published within 180 days of purchase, you will get the revised report free of charge
Datasheet Licence
$1500.00
  • Report accessible by 1 user only
  • Free 15% or 32 hours of customization
  • Free post-sale service assistance
  • Direct access to lead analysts

Select a license type that suits your business needs

Best Value Tag
Coming Soon
  • Stay tuned with us.

YOU CAN GET A FREE SAMPLE OF THIS REPORT!

Fill out your details & get your free sample

Our Clients

Prebook Tag
Licence Types What are these?
10 % OFF

Save 10% on this report.
Discount already applied

Our Clients Speak

"The report by Arizton was spot on. It not only gave us insight into the pro audio market, we used it to raise funds for our company. The data proved (to the VC we pitched to) that the market was large enough for our company to not only survive but also grow."

Erik Young
CEO, Co-founder
Audink Inc., DBA Audios
SPEAK WITH OUR ANALYST

Want to know more about the report or any specific requirement?

Click to Email +1-312-235-2040

Why Arizton?

  • 100% Customer Satisfaction
  • 24x7 availability – we are always there when you need us
  • 200+ Fortune 500 Companies trust Arizton's report
  • 80% of our reports are exclusive and first in the industry
  • 100% more data and analysis
  • 1000+ reports published till date